Please login first

The 3rd International Electronic Conference on Cancers: New Targets for Cancer Therapies (IECC 2023)

Part of the International Electronic Conference on Cancers (IECC) series
16–30 Mar 2023

Cancer, Cancer Genomics, Epigenomics, Cancer Epidemiology, Cancer Research
Bookmark event Remove event from bookmarks
Add this event to bookmarks
Contact Us

The recordings of IECC 2023 live sessions are available at:

All participants of IECC 2023 are welcome to submit an extended full paper to the Special Issue "IECC2023: New Targets for Cancer Therapies" of the journal Cancers, with a 20% discount on the Article Processing Charges.

The IECC 2023 award winners have been announced at

Registration for IECC 2023 live sessions is open now

There will be two live sessions, all of which are completely free to attend. There is a different registration link for each live session. You only need to register for the ones that you wish to join. If you would like to attend more than one live session, please register for each session separately.

Registrations with academic institutional email addresses will be prioritized.

Welcome from the Chair

Dear colleagues,

We are pleased to announce the 3rd International Electronic Conference on Cancers: New Targets for Cancer Therapies (IECC 2023), which will be held from 16–30 March 2023.

The opportunities for new therapeutic targets have expanded tremendously. In recent years, cancer genomics has expanded our view of cancer vulnerabilities, new technologies have changed the paradigm of what can be successfully targeted, and new immunotherapy targets are emerging rapidly. This conference aims to promote and advance the coordinated progress in oncology research to foster the development of innovative therapeutic strategies. It will bring together experts in basic, translational, and clinical research to discuss the current research and the opportunities as well as obstacles that lie ahead in the field.

The focus of this conference is the translation of recent discoveries into new therapeutic targets for cancer therapies. Topics of interest include, but are not limited to, the following:

  • Translational cancer genomics and epigenomics.
  • Emerging immunotherapy targets.
  • Overcoming therapeutic hurdles in resistance and undruggable proteins.

There will be five specific sessions:

Session 1: Genome-wide Approaches for Target Identification.
Session 2: Targeting Metastasis.
Session 3: Novel Immunotherapy Targets.
Session 4: Novel Approaches for ‘Undruggable’ Targets.
Session 5: Overcoming Therapeutic Resistance.

Participants will have the opportunity to examine, explore, and critically engage with issues and advances in these areas. We hope to facilitate discussions and exchange within the community.

This event will solely be an online proceeding, which allows for participation from all over the world with no concerns of travel and related expenditures. This type of conference is particularly appropriate and useful because research concerned with cancers is progressing rapidly. An electronic conference provides a platform for rapid and direct exchanges about the latest research findings and novel ideas. Participation in, as well as the “attendance” of, this online conference is free of charge.

This electronic conference is sponsored by MDPI and the scientific journal Cancers. The accepted conference proceedings papers and presentations will be available online for discussion during 16–30 March 2023 and will be published in the journal Medical Sciences Forum. All participants are cordially encouraged to submit an extended full manuscript to the Cancers conference Special Issue "IECC2023: New Targets for Cancer Therapies" with a 20% discount on the APC. Cancers (ISSN 2072-6694; IF 6.575) is a peer-reviewed and open access journal of oncology that is published semimonthly online by MDPI.

The best paper will receive an award of CHF 500, and the best presentation (poster, slides, or video) will receive an award of CHF 300. Both will also receive an offer to publish an extended paper, with a 20% discount, in a Special Issue "IECC2023: New Targets for Cancer Therapies" of the journal Cancers.

We hope that the community will share this enthusiasm and help make this conference a success.

Kind regards,
Dr. Carlos S. Moreno
The Chair of the 3rd International Electronic Conference on Cancers: New Targets for Cancer Therapies

Follow the conference organizer on Social Media

Live Session Program

Live Session 1

20 March 2023
3:00 pm CET | 10:00 am EDT | 10:00 pm CST Asia
Session Chair: Prof. Dr. Nicola Amodio


Presentation Topic

Time (CET)

Prof. Dr. Nicola Amodio



Dr. Andrea Morandi

Lipid metabolism is a vulnerability of endocrine-resistant breast cancers


Dr. Mariateresa Fulciniti

Targeting myeloma at the intersection between cell cycle, metabolism and transcriptional regulation to repress growth and overcome resistance


Prof. Dr. Nicola Amodio



Live Session 2

28 March 2023
3:00 pm CEST | 9:00 am EDT | 9:00 pm CST Asia
Session Chair: Dr. Francisca Vazquez


Presentation Topic

Time (CET)

Dr. Francisca Vazquez



Dr. Francesco Iorio

Optimisation and drug-discovery oriented analyses of CRISPR-Cas9 screens


Dr. Travert Hart

Multiplex perturbation strategies for genetic modeling of drug response


Dr. Davide Barbagallo

The complex crosstalk among non-coding RNAs: the case of circSMARCA5 in glioblastoma multiforme


Prof. Dr. Vasso Apostolopoulos

Identification of new cancer markers: a way forward


Dr. Francisca Vazquez



Live Session Recordings

To view this content, you need to be registered and logged in to Sciforum platform.

Event Chair

Department of Pathology and Laboratory Medicine, Emory University School of Medicine, USA

Carlos S. Moreno, PhD, is an Associate Professor in the Departments of Pathology and Laboratory Medicine, and Biomedical Informatics at the Emory University School of Medicine. He is a member of the Cell and Molecular Biology Research Program at Winship Cancer Institute. Dr. Moreno specializes in cancer bioinformatics and systems biology, analysis of genome-wide expression profiles, transcriptional networks, ChIP-chip studies, biological pathway analysis, and computational analysis of transcription factor binding sites. Dr. Moreno is project leader for informatics for the Emory Molecular Interaction Center for Functional genomics (MicFG) as part of the Cancer Target Discovery and Development (CTD²) Network to analyze TCGA data for protein-protein interaction networks.

Session Chairs

Prof. Dr. Frank McCormick

UCSF Helen Diller Family Comprehensive Cancer Center, School of Medicine, University of California, USA; NCI RAS Initiative, Cancer Research Technology Program, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research, USA

Short Bio
Frank McCormick, PhD, FRS, is a Professor in the UCSF Helen Diller Family Comprehensive Cancer Center. Prior to joining the UCSF faculty, Dr. McCormick pursued cancer-related work with several Bay Area biotechnology firms and held positions with Cetus Corporation and Chiron Corporation, where he was Vice President of Research from 1991 to 1992. Dr. McCormick holds the David A. Wood Chair of Tumor Biology and Cancer Research at UCSF. Dr. McCormick is the author of over 285 scientific publications and holds 20 issued patents. He also served as President, 2012-2013 for the American Association for Cancer Research (AACR). More recently, he has taken a leadership role at the Frederick National Lab for Cancer Research, overseeing an NCI supported national effort to develop therapies against Ras-driven cancers. These cancers include most pancreatic cancers, and many colorectal and lung cancers, and are amongst the most difficult cancers to treat.

Dr. Francisca Vazquez

Broad Institute of MIT and Harvard, USA

Short Bio
Francisca Vazquez is the director of the Cancer Dependency Map Project (DepMap) at the Broad Institute, a programmatic effort that she co-leads to systematically identify all cancer dependencies in human cancer. The DepMap project is an effort to comprehensively identify genetic dependencies and small molecules sensitivities and the molecular markers that predict their response across thousands of cancer cell line models to accelerate precision cancer medicine. To accomplish this goal, Vazquez works with a large interdisciplinary team of project managers, basic scientists, and computational biologists that uses state-of-the-art genome-scale functional genomics, including CRISPR and high-throughput small molecule screening technologies, to systematically profile hundreds of cellular models of cancers. Vazquez also leads DepMap’s target discovery and advancement team, which focuses on developing methods to systematically identify the most promising therapeutic targets and translate the findings to therapeutics. Vazquez launched the Pediatric and Brain Tumor dependency maps, which she co-leads to more rapidly advance therapeutic discoveries in those tumor types. Her main goal is to help accelerate precision cancer medicine by both creating resources for the scientific community, such as DepMap, and identifying and validating the most promising targets and biomarkers. Prior to joining the Broad Institute in 2011, Vazquez worked as a research scientist at Dana-Farber Cancer Institute in the center for chronic disease, studying cancer metabolism; her postdoctoral work, which focused on tumor suppressor genes, was also undertaken at DFCI. She earned her Ph.D. from the University of Illes Balears in Spain, while performing most of her work as a visiting student at Beth-Israel Deaconess Medical Center.

Prof. Dr. Nicola Amodio

Department of Experimental and Clinical Medicine, Magna Graecia University of Catanzaro, Italy

Short Bio
Nicola Amodio, Ph.D., joined the University Magna Graecia of Catanzaro (I) in 2002 as a PhD fellow in “Molecular Oncology”, focusing on transcription factors dysregulation in normal and malignant hematopoiesis. After a Post-Doctoral fellowship at MSKCC (NY, USA) in 2006, he returned at University of Catanzaro as a Senior Scientist, focusing on the discovery of genetic and epigenetic alterations driving the development of solid and hematologic malignancies, and on the design of innovative anti-cancer therapies. Since 2019, Dr. Amodio works as Assistant Professor, and since 2022 he has been appointed Associate Professor of “General Pathology” at the Department of Experimental and Clinical Medicine, University Magna Graecia of Catanzaro (I). He serves as editor in chief for the journal “Cancers”, section “cancer pathophysiology”. His current research, supported by the Italian Association for Cancer Research (AIRC), is aimed at the identification and characterization of novel druggable vulnerabilities underlying the pathogenesis and progression of plasma cell dyscrasias by using integrated functional and (epi)genomics analyses.

Event Committee

Program of Immunology and Immunotherapy. Cima Universidad de Navarra, Spain

Pedro Berraondo, Ph.D., is a staff scientist at the Cima Universidad de Navarra. He is a co-inventor of eight patents, and co-author of more than 140 publications including publications in Nature, Nature Medicine, Nature Reviews Drug Discovery, Immunity, Cancer Discovery, and Cancer Cell. He is co-director of the degree of an expert in immuno-oncology at the Faculty of Medicine of the University of Navarra, and the coordinator of the immuno-oncology work module at CIBERONC.
Research Keywords
Cancer immunotherapy; fusion proteins; gene therapy

Program of Hepatology. Cima. University of Navarra, Spain

Dr. Avila is Professor of Biochemistry and Molecular Biology and director of the Hepatology Program of the Center for Applied Medical Research at the University of Navarra, Pamplona, Spain. His research interests include the cellular and molecular mechanisms of the hepatic response to acute injury and regeneration, as well as the genetic mechanisms of chronic liver disease progression and carcinogenesis, with a basic and translational perspective. Research for the identification of novel biomarkers for the early diagnosis of hepatobiliary malignancies in the context of liquid biopsy is also pursued in his laboratory.
Research Keywords
hepatocarcinogenesis; cell signaling; differentiation; epigenetics

Department of Agricultural Sciences University of Naples Federico II, Italy

Degree in Parmacy (1996); Master in Medicinal Plants (2000); Master in Pharmacology (2002); PhD in Drug Science (2005). TEACHING EXPERIENCE: Professor of Pharmacognosy at the University of Naples Federico II. MAIN RESERCH INTERESTS: Role of cannabinoid, vanilloid and kappa-opioid receptors in the gastrointestinal tract, both in physiological (e.g. intestinal motility) and pathophysiological states (e.g. inflammation and cancer); Ethnopharmacological studies on medicinal plants and their active ingredients used in traditional medicine; Clinical pharmacology of herbal products; Nutritional pharmacology. PUBLICATIONS: 190 articles in peer-reviewed international Journals (cited in JCI). AWARDS: Farmindustria Prize (year 2006), from the Italian Society of Pharmacology, to the best article published by researcher under 35 years as a first author.
Research Keywords
pharmacology; natural products; neurotransmission; behavioral pharmacology; experimental pharmacology; preclinical pharmacology; CB1 receptor; PPARs; cannabinoids; endocannabinoids; CB2 receptor

Department of Experimental and Clinical Biomedical Sciences, Experimental Pathology and Oncology, University of Florence, Italy

Francesca Bianchini is a tenured associate professor in General Pathology at the University of Florence involved in teaching to Medicine and Surgery, and Nursing students. After graduating in Biological Sciences, she received her training on preclinical oncology, under the supervision of Prof. Calorini, at the University of Florence. She obtained her PhD in Experimental Pathology from the University of Florence in 2002. During her PhD, she attended the laboratory of Prof. Charles N. Serhan at the B&WH Harvard Medical School in Boston (MA). Her post-doctoral research has been extensively focused on preclinical oncology and translational medicine.
Research Keywords
tumor microenvironment (TME); cancer cell biology; extracellular acidity; nanomedicine; targeted drug delivery and personalized anticancer therapy

Cancer Biomarkers Unit, Fondazione IRCCS Casa Sollievo della Sofferenza, Italy

He worked as postdoctoral fellow at the FIRC Institute for Molecular Oncology (IFOM), Milan (Italy), and then at the Program of Molecular Medicine of the European Institute of Oncology (Milan). He was a visiting scientist at the Nuffield Department of Clinical and Laboratory Sciences at University of Oxford. Since 2016 he has been the Head of the Cancer Biomarkers Unit at the Research Hospital (IRCCS) Casa Sollievo della Sofferenza. He has several years of research experience in the fields of cancer genomics and biomarkers development, particularly in the field of circulating miRNAs, cancer gene expression profile and computational biology. He has pioneered the identification of serum circulating miRNA-signature for lung cancer early detection. He is inventor of international patents regarding diagnostic and prognostic tools for lung cancer screening. He is an active member of the American Association for Cancer Research (AACR), the European Association for Cancer Research (EACR), the International Association for the Study of Lung Cancer (IASLC), the Italian Society for Cancer Research (AIRC), and the Italian Society of Cancerology (SIC), where he holds the positions of secretary and member of the steering committee.
Research Keywords
lung cancer; molecular oncology; gene expression; cancer biomarkers; microRNA; exosomes

Department of Internal Medicine-DIMED, Internal Medicine and Hepatology Unit, University-Hospital AOUP, Italy; Responsible of the Out-patient Unit of the Veneto Specialized Center on Liver Diseases, AOUP, Italy

- Degree in Medicine and Surgery at the University of Padua (UNIPD), Italy on 03/28/83 - Qualification as a Surgeon in the 1st 1983 session with registration N°5037 on 05/07/1983 to the Order of Physicians and Surgeons of Padua, Italy. - Specialization in Internal Medicine at UNIPD on 07/15/88. - Graduate Technical Assistant at the UNIPD-Institute of Clinical Medicine from 1991 to 1997. - Level I Medical Director in Internal Medicine-Hospital of Padua since 06/1991. - PhD in Clinical Pharmacology and Medical Therapy at UNIPD in 1993. - Confirmed Researcher and Adjunct Professor from 2006 to 2015 and - Confirmed Associate Professor of Internal Medicine from 10/01/2015 of the Department of Medicine-DIMED at UNIPD.
Research Keywords
clinical and epidemiological features of chronic hepatitis C and B and its antiviral treatments; cirrhosis and complication of evolutive liver disease; natural history and treatment of hepatocellular carcinoma; transient elastography for staging of chroni

Translational Research Institute, Hamad Medical Corporation, Qatar

Dr. Aamir Ahmad is a Senior Research Scientist and Group Leader at Academic Health System and Dermatology Institute, Translational Research Institute, Hamad Medical Corporation (HMC). Before joining HMC, he was a Senior Research Scientist at University of Alabama at Birmingham, Birmingham, AL, USA. Dr. Ahmad holds a PhD degree from AMU, Aligarh, India and completed his post-doctoral training at National Cancer Institute, National Institutes of Health, Bethesda, MD, USA. He has authored more than 200 peer-reviewed publications (h-index: 68) and 30 book chapters, in addition to editing books for leading publishing houses and serving on the editorial board of several International Journals of repute. Dr. Ahmad’s research focuses on epigenetic regulation of disease progression, particularly cancer and skin diseases.
Research Keywords
cancer epigenetics; metastasis; cancer drug resistance; tumor microenvironment; miRNA; non-coding RNAs; cancer stem cells

Department of Pathology, Department of Anatomy & Cell Biology, Rush University Medical Center, USA

Jeffrey A. Borgia, PhD. is a graduate of the Biochemistry Graduate program at the University of Minnesota where he performed research in the field of proteoglycan biosynthesis in the laboratory of Dr. Theodore R. Oegema, Jr. During his post-doctoral studies, he collaborated with Dr. Gregg B. Fields where he explored the production of matrix metalloproteinases by melanoma cells when adhered to synthetic ‘mini-collagens’ as well as tumor cell aggressiveness. In 2002, Dr. Borgia joined the faculty at Rush in the Department of Biochemistry and launched his program focused on cancer biology and the development of novel diagnostic tests with Dr. John S. Coon, IV in the Department of Pathology. He is currently continuing these studies with appointments in both the Department of Cell & Molecular Medicine and Department of Pathology.
Research Keywords
lung cancer; biomarkers; cancer cachexia; immunotherapy; recurrence; lung cancer screening; early detection; EMT; proteomics; biobanking

Laboratory of Biololy and Modeling of the Cell (LBMC), France

His team is working on RNA metabolism, including alternative splicing, and on the role of RNA metabolism in the phenotypic plasticity of cancer cells, including in response to anti-cancer therapies. His expertise is notably based on the use of original bioinformatics analysis approaches.
Research Keywords
Splicing; Splicing Factors; RNA Binding Proteins; RNA Processing.

Instituto de Investigaciones Biomédicas Alberto Sols (CSIC-UAM), Arturo Duperier

Lisardo Boscá graduated with a Ph.D. in sciences from the University of Autónoma de Madrid. In the last decade, Dr. Lisardo Boscá has been working in the regulation of inflammation as a common pathophysiological process, from inception to resolution, and applied this knowledge to understand the pathogenesis of processes that are relevant in cardiovascular diseases. In 2010, in a paper published in J. Immunol., with more than 600 citations, Dr. Lisardo Boscá described the metabolic features associated with the phenotypic differentiation of macrophages, from a pro-inflammatory to an anti-inflammatory and pro-resolution profile. In addition to this, Dr. Lisardo Boscá has shown for the first time how bioactive lipids derived from cyclooxygenase and/or lipooxygenases are involved in the resolution of several cardiovascular pathologies, from atherothrombosis to myocardial infarction to autoimmune myocarditis.
Research Keywords
cancer immunometabolism; cancer therapeutics; apoptosis; immunotherapy; cancer metabolism; colorectal cancer

INSERM UMR 1186, Integrative Tumor Immunology and Genetic Oncology, Gustave Roussy, EPHE, Fac. de médecine-Univ. Paris-Sud, University Paris-Saclay, France

CHOUAIB Salem graduated with a Ph.D. in Immunology from Pierre et Marie Curie University, Paris VI. Serve as a member of the The selection committee at René Descartes University (Paris V) from 2012-present; Serve as a member of the council “Studium of Molecular Medicine” international doctorate school in Warsaw Poland from 2005-present; Serve as a member of the Scientific Steering Committee of Aix-Marseille University from 2015-present; Serve as a member of the international council in Pasteur Institute (Tunisia) from 2014-present; Serve as a member of ITMO Cancer as the coordinator of cancer immunotherapy section from 2011-present. The current research interests: immunology of cancer, Cancer Immunotherapy, Tumor microenvironment and mechanisms of carcinoma invasion, Cell-mediated cytotoxicity and tumor resistance and Translational research in Oncology.
Research Keywords
integrative tumour immunology; cancer immunotherapy; genetic oncology

Professor of Pathology and Immunology, Medical Director, Division of Clinical Immunopathology, University of Pittsburgh Medical Center, USA

After graduation from Moscow State Medical School in 1984, postgraduation training in clinical biochemistry and clinical immunology and obtaining his PhD degree in Immunopharmacology in 1991, Dr. Shurin joined the faculty of the Department of Pathology at the University of Pittsburgh Medical Center in 1991 where he is a Professor of Pathology and Immunology and a Director of the Division of Clinical Immunopathology. His main research interests are in the field of the tumor microenvironment, cancer-mediated immunomodulation and solid tumor innervation. Professor Shurin’s pioneering studies on the immunobiology of dendritic cells in cancer opened opportunities for developing novel therapeutic approaches that are based on the protection of dendritic cell vaccines from tumor-mediated immunosuppression and polarization. At present, Shurin’s research program focuses on the immune modulating properties of chemotherapy and modulation of the tumor microenvironmental elements, including dendritic cells, regulatory T cells, myeloid-derived suppressor cells and neuroglial cells, as well as intratumoral cytokine network. Using a combination of immunological, molecular and gene therapeutic methodologies, Dr. Shurin’s team developed innovative immunotherapeutic, chemoimmunotherapeutic and nanotherapeutic approaches for cancer, which were successfully tested in the pre-clinical settings and are under investigation in clinical trials. Professor Shurin is an author of more than two hundred peer-reviewed publications and numerous reviews, an editor of several books, including “Dendritic Cell in Cancer”, “Infection and Cancer” and “The tumor immunoenvironment” books, an organizer of several popular international conferences on Immune-Mediated Diseases, Immunodiagnostics and Immunomonitoring and Cancer Immunotherapy. He is a member of several grant review and editorial boards and many clinical and research societies.

Institute of Molecular and Cellular Biology, Faculty of Biological Sciences, University of Leeds, UK

He studied Biochamistry at the University of Edinburgh and performed doctoral studies at the University of Warwick. He did postdoctoral research in the universitites of Aarhus, Denmark and Uppsala, Sweden. He was a member of the SCientific Staff of the National Institute of Medical Research, London (now the Crick Institute). He was appointed as Lecturer in BIochemistry in 1981, Senior Lecturer in 1988, Reader in 1996 and Professor in 2008.
Research Keywords
Oncogenic viruses; Papillomaviruses;Virotherapy; Oncolytic viruses; Cancer gene therapy; Cancer immunotherapy

Keynote Speakers

Dr. Francesco Iorio
Computational Biology Research Centre of Human Technopole

Short Bio
Francesco Iorio is a Research Group leader in the Computational Biology Research Centre of Human Technopole (the life science institute in Milan, Italy). His group works at the interface of biology, machine learning, statistics and information theory to understand and predict how genomic alterations and molecular traits from other omics contribute to pathological processes, biological circuits’ rewiring and impact therapeutic responses in human cancers and other diseases.

Their research aims to advance human health by designing algorithms, computational tools and novel analytical methods for integrating and analysing pharmacogenomics and functional-genomics datasets to identify new therapeutic targets, biomarkers and drug repositioning opportunities.

The Iorio Group is contributing to creating a comprehensive map of all the genetic dependencies in human cancers and developing a computational infrastructure for translating this map into guidelines for early-stage drug development and precision medicine.

They design, implement and maintain bioinformatics methods and original tools for the assessment of cancer pre-clinical models, the pre-processing, analysis and visualisation of genome-editing screening data for the in-silico correction of new-technology-specific biases in such data, and the optimisation of single guide RNA libraries for pooled CRISPR-Cas9 screens and other experimental settings.

They are also interested in big-data analytics, developing biomedical predictive models based on non-biomedical data, and computationally efficient constrained randomisation strategies for testing combinatorial properties in large-scale genomic datasets and networks.

Dr. Travert Hart
Department of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, USA.
Department of Cancer Biology, The University of Texas MD Anderson Cancer Center, USA.

Short Bio
The Hart Lab at MD Anderson studies the functional genomics of cancer using a combination of high-throughput experiments and integrated computational analysis. They start with the principle of synthetic lethality, where a genomic modification to one gene (through mutation, copy number change, or silencing) causes cells to be dependent on other genes and pathways. They perform systematic, genome-scale gene knockout screens using the CRISPR-Cas9 system [Hart et al, Cell, 2015] in cancer cell lines and analyze them using BAGEL, a state-of-the-art algorithm developed in the lab [Hart et al, BMC Bioinformatics, 2016]. Finally, They integrate our analyses with other molecular data profiling the DNA, RNA, protein, and metabolic state of the cells. While in the short term They seek to match tumors with effective drugs and to identify new drug targets where current drugs are lacking, our long-term goal is a deeper understanding of the coincident sets of a biological process that cancer cells rely on for growth and metastasis, and ultimately a predictive model of response to therapies that eliminates tumors while anticipating and preventing acquired resistance.

Within the framework of these overarching goals, a wide array of tutorial projects are possible. Computational projects could include reanalysis of existing data to improve our ability to detect gene-gene and gene-drug interactions, enhancing the BAGEL algorithm to include other molecular data such as gene expression and copy number, or helping evolve BAGEL from a gene-centric to a pathway-centric model. Experimental tutorials could involve any aspect of a CRISPR genomic screen, from lentiviral library construction to large-scale tissue culture, screening, and sequencing, and ultimately to validation and characterization of specific targets using small molecule inhibitors, automated microscopy, and other proteomic and phenotypic assays.

Dr. Andrea Morandi
Department of Experimental and Clinical Biomedical Sciences, University of Florence, Italy

Short Bio
Andrea Morandi is Associate Professor of Biochemistry at the University of Florence. He studied Biotechnology(BSc)and Medical Biotechnology (MSc) at the University of Florence and gained is BSc in 2004 and MSc in 2006 both with honors, after a period of research on MAPK signaling in liquid and solid cancers. immediately after the MSc, Andrea started a Ph.D. on the role of
Tyrosine Kinase Receptors in breast cancer. In 2007, he moved to the Institute of Cancer Research in London in the laboratory of Prof Clare lsacke where he investigated, first as visiting Ph.D. student and then as a Worldwide Cancer Research supported postdoctoral fellow, the role of the receptor tyrosine kinase RET in response and resistance to endocrine therapy in breast cancer.
In 2013, Andrea was awarded a Fondazione Italiana per la Ricerca sul Cancro Fellowship and returned to Florence. He then obtained the Fondazione Umberto Veronesi fellowship for three consecutive calls (2016-2018) before becoming Faculty at the University of Florence.

Dr. Mariateresa Fulciniti
Department of Medical Oncology, Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Boston, USA.
Harvard Medical School, USA.

Short Bio
Dr. Fulciniti received her BS/MS degree in biological sciences from the University of Calabria, Italy in 2004. She obtained a PhD in Molecular Oncology from the University of Magna Graecia, Italy in 2009, after spending two years as visiting PhD student at Dana-Farber Cancer Institute, Boston, USA. In 2013, she became Instructor in Medicine at the Harvard Medical School. She’s currently Lead Scientist in Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute.
Dr Fulciniti’s research is an example of the Bench to Bedside and Bedside to Bench translational research approach. Her research focuses on identifying new druggable dependencies and developing novel therapeutic strategies for the treatment of multiple myeloma and related plasma cell disorders. Specifically, her research aims at elucidating key cellular signaling pathways that contribute to the survival and proliferation of myeloma cells in the microenvironment, including immune escape, as well as the mechanisms driving intrinsic and acquired drug resistance in myeloma by integrative epigenomic and genomic parameters. She has published widely on multiple myeloma and is an ad hoc reviewer for several journals including Blood and Clinical Cancer Research.

Prof. Dr. Vasso Apostolopoulos
Institute for Health and Sport, Victoria University, Australia

Short Bio
Vasso is the Leader of the Immunology and Translational Research Group at Victoria University Australia and the Vice-Chancellors Distinguished Fellow.

Her expertise is multi-disciplinary with extensive expertise in immunology, x-ray crystallography, medicinal chemistry, cellular biology, clinical research. She has extensive translational research expertise with development of drugs and vaccines. Vasso has undertaken research and led Programs in various capacities at Oxford University, Scripps Research Institute USA, Queensland, Canberra and in Melbourne. She was the head of the Immunology & Vaccine Unit at the Austin Research Institute and at the Burnet Institute; the Immunology Program Leader in the Centre for Chronic Disease; was the Mechanisms and Interventions in Health and Disease Program Leader at VU. In 2018-2022 she was part of the senior executive team at VicUni being the Deputy Vice-Chancellor Research, and Pro Vice-Chancellor, Research Partnerships.

Vasso has extensive expertise in vaccine and drug development with over 25 phase I, II, III human clinical trials of her work on cancer. Committed to the benefits of immunotherapy, Vasso has applied several immunotherapies to other diseases including for MS, T1D, drug addiction and neurodegenerative diseases. Her work is also based on understanding mechanisms and developing interventions for cancer, chronic-, infectious- and autoimmune diseases, using either vaccines, drugs, natural bio-active compounds or via physical activity. She is committed to driving her research and programs to help people age healthy. To date Vasso has published over 500 research papers and is an inventor on 20 patents.

Dr. Davide Barbagallo
Department of Biomedical and Biotechnological Sciences,
University of Catania, Catania, Italy

Short Bio
Davide Barbagallo is a tenure-track Assistant Professor at University of Catania, Italy. Davide did his PhD studies in the lab of Professor Michele Purrello, University of Catania, working on the involvement of the apoptotic machinery in the etiology of diabetes mellitus. Following this, in 2009, he started his Postdoc activity in the same lab where he focused on the study of non-coding RNA, especially microRNAs, and their involvement in diabetes mellitus and cancer. In 2010, his PhD thesis was awarded as the best in the field of complex biological systems from the Gioenian Academy. In 2017 he was awarded the Umberto Veronesi Foundation Post-doctoral fellowship and he joined Professor Jørgen Kjems’ non-coding RNA lab, University of Aarhus, Denmark, where he spent 6 months to improve his knowledge on circular RNAs (circRNAs), another class of (mostly) non-coding RNAs, recently discovered as critical regulators of gene expression. During his stay at the non-coding RNA lab, under the tutorship of Dr. Thomas Birkballe Hansen, Davide cloned the sequence of circSMARCA5 into an expression vector and showed the tumor suppressive function and mechanism of action of this circRNA in glioblastoma multiforme. In 2018, Davide got back to University of Catania, at the Department of Biomedical and Biotechnological Sciences where he has continued his work on circRNAs.

List of accepted submissions (13)

Id Title Authors Presentation Video Poster PDF
sciforum-067173 Potential Candidate Gene in Underlying Molecular Mechanism Involving in Tumorigenesis of Endometriosis-associated Ovarian Cancer (EAOC) in Asian Populations

, ,

Submitted: 04 Jan 2023

Abstract: Show Abstract
, , N/A N/A Show Abstract
sciforum-068576 5-Nitroindazole against Lung Cancer: A multitargeted in-silico molecular docking and Molecular Dynamics simulation study


Submitted: 09 Dec 2022

Abstract: Show Abstract
, Video Thumbnail Poster PDF Show Abstract
sciforum-067497 A combination of Vitamin C with DNA methylation inhibitor Decitabine Preserves the Colon Immunogenicity and Overcomes the Chemoresistance , , , , , , N/A Poster PDF Show Abstract
sciforum-069082 Lentiviral transduction of rat adipose-derived stem cells for stable production of TRAIL in the tumour microenvironment in an in-vitro model of breast cancer

, ,

Submitted: 22 Dec 2022

Abstract: Show Abstract
, , N/A Poster PDF Show Abstract
sciforum-069225 Amelioration of Glioblastoma multiforme by the combintion of Simulated microgravity and Oncolytic viral therapy.


Submitted: 30 Dec 2022

Abstract: Show Abstract
, N/A Poster PDF Show Abstract

Instructions for Authors


Submissions should be made by authors online by registering with, and using the "New Submission" function once logged into the system.
Note: Institutional email address is requested especially for the corresponding author. Please submit the abstract with the institutional email address.

Scholars interested in participating in the conference can submit their abstract (about 200–300 words) online on this website until 5th January 2023. The Conference Committee will notify the acceptance of the abstract by 31st January 2023 .

In case of acceptance, authors will be asked to submit their manuscript (short proceedings paper, 3-6 pages) before 13th February 2023. Optionally, authors of accepted abstracts will be able to submit a poster, a slides presentation (in PDF) and/or a short video presentation (max. 3-5minutes) as supporting material for the paper. Authors will receive a notification about the acceptance of their papers by 20 February 2023.

Note: All submissions will be reviewed using the powerful text comparison tool iThenticate. This procedure aims to prevent scholarly and professional plagiarism. Submissions will then be peer-reviewed by conference committees based on originality/novelty, quality of presentation, scientific soundness, interest to the readers, overall merit and English level. After the conference, all submissions will be published on, and only the proceeding paper (3-6 pages) will be published in the MDPI Medical Sciences Forum journal (ISSN 2673-9992).
Note: Publication of proceedings paper is free of charge.
Before publication, Medical Sciences Forum journal (ISSN 2673-9992) journal will check the plagiarism issue again. Submissions with a lack of novelty will not be published in the journal.

All participants of IECC2023 are welcome to submit an extended full paper to the conference Special Issue "IECC2023: New Targets for Cancer Therapies" of the journal Cancers, with a 20% discount on the Article Processing Charges.

Proceedings Paper

Proceedings papers must be prepared in MS Word using the (see below) and should be converted to PDF format before submission. The manuscript should count at least 3 pages (incl. figures, tables and references) and should not exceed 6 pages. Carefully read the rules outlined in the 'Instructions for Authors' on the journal website and ensure that your manuscript submission adheres to these guidelines.

Manuscripts for the proceedings issue must have the following organization:

  • Title
  • Full author names
  • Affiliations (including full postal address) and authors' e-mail addresses
  • Abstract
  • Keywords
  • Introduction
  • Methods
  • Results and Discussion
  • Conclusions
  • (Acknowledgements)
  • References
Presentation Slides

Authors are encouraged to prepare a presentation in PowerPoint or similar software, to be displayed online along with the manuscript. Slides can be prepared the same way as for any traditional conference. They should be converted to PDF format before submission.

Video Presentations

Authors are requested to submit video presentations accompany with extended submissions. Video should be no longer than 3-5 minutes and prepared with one of the following formats: .mp4 / .webm / .ogg (max size: 250Mb). It should be submitted with the full manuscript before 16 January 2023 (full submission deadline).


Posters will be available on this conference website during and after the event. Like papers presented on the conference, participants will be able to ask questions and make comments about the posters. Posters can be presented without an accompanying proceedings paper. However, they will not be added to the proceedings of the conference.

After acceptance, please upload a copy of the proceedings/abstract as a PDF and word, in the corresponding fields, and upload the Poster PDF in the field "Presentation PDF (optional)".

1)The poster should be in PDF format
2)The minimum size for images is 148 mm × 210 mm (horizontal × vertical) at 300 dpi.
3)The content of the poster should be a comprehensive presentation of your accepted submission.
4) No copyright issues with any elements in the poster.

For detailed instructions on how to submit a poster, please contact us.

Potential Conflicts of Interest

All authors must disclose all relationships or interests that could inappropriately influence or bias their work. This should be conveyed in a separate "Conflict of Interest" statement preceding the "Acknowledgments" and "References" sections at the end of the manuscript. If there is no conflict, please state "The authors declare no conflict of interest." Financial support for the study must be fully disclosed under the "Acknowledgments" section.


MDPI, the publisher of the platform, is an open access publisher. We believe that authors should retain the copyright to their scholarly works. Hence, by submitting a communication paper to this conference, you retain the copyright of your paper, but you grant MDPI the non-exclusive right to publish this paper online on the platform. This means you can easily submit your paper to any scientific journal at a later stage and transfer the copyright to its publisher (if required by that publisher).

Event Awards

Winner Announcement

On behalf of the chairs of IECC 2023, we are pleased to announce the winner of the Best Paper Award:
sciforum-069265, "Novel therapeutic approaches for kras mutated lung cancer involving Lztr1 genetic alteration"
Raj Sewduth, Tonci Ivanisevic, Peihua Zhao, and Anna Sablina
The Award consists of 500 CHF and a certificate.

On behalf of the chairs of IECC 2023, we are pleased to announce the winner of the Best Presentation Award:
sciforum-069402, "Multi-omics analysis of NFE2L2 mutated TCGA-Cervical Squamous Cell Carcinoma patients"
Sri Vidya Ramisetti and Akhileshwar Namani
The Award consists of 300 CHF and a certificate.

The Awards
Best Paper Award and Best Presentation Award

Number of Awards Available: 1

Best Paper Award:The Best Paper Award is given to the paper judged to make the most significant contribution to the conference. There will be one winner selected for this award, the winner will receive a certificate and 500 CHF.

Best Presentation Award:The Best Paper Award is given to the paper judged to make the most significant contribution to the conference. There will be one winner selected for this award, the winner will receive a certificate and 300 CHF.

Conference Secretariat

Ms. Rainy Han
Ms. Simon You
Ms. Alethea Liu

MDPI Branch Office, Beijing

Sponsors and Partners


Media Partners